Claims
- 1. A compound of formula (I)
- 2. A compound of claim 1, wherein:
R′ is 20wherein R is selected from the group consisting of chloro, fluoro, and methyl; R″ is 21R′″ is hydrogen or methyl; and Z is oxygen.
- 3. A compound of claim 1, wherein:
R′ is 22wherein R is selected from the group consisting of chloro, fluoro, and methyl; R″ is 23R′″ is hydrogen or methyl; and Z is oxygen.
- 4. A compound of claim 1, wherein:
R′ is 24wherein R is selected from the group consisting of chloro, fluoro, and methyl; R″ is 25R′″ is hydrogen; and Z is oxygen.
- 5. A compound of claim 1 selected from the group consisting of:
5-chloro-1H-indole-2-carboxylic acid-(1-benzyl-3-(1,1-dioxo-tetrahydro-1-thiophen-2-yl)-2-hydroxy-3-oxo-propyl]-amide; 5-chloro-1H-indole-2-carboxylic acid-(1-benzyl-3-(1,1-dioxo-1-tetrahydro-1-thiophen-2-yl)-2-methoxy-3-oxo-propyl]-amide; 5-chloro-1H-indole-2-carboxylic acid-[1-benzyl-3-(1,1-dioxo-hexahydro-1-thiopyran-2-yl)-2-methoxy-3-oxo-propyl]-amide; and 5-chloro-1H-indole-2-carboxylic acid-[1-benzyl-3-(1,1-dioxo-hexahydro-1-thiopyran-2-yl)-2-hydroxy-3-oxo-propyl]-amide; the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs.
- 6. A compound of claim 1, wherein
R′ is 26R″ is 27R′″ is methyl; and Z is oxygen.
- 7. A compound of claim 1, wherein:
R′ is 28R″ is 29R′″ is hydrogen or methyl; and Z is oxygen.
- 8. A compound of claim 1 selected from the group consisting of:
2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid-[1-benzyl-3-(1,1-dioxo-tetrahydro-1-thiophen-2-yl)-2-hydroxy-3-oxo-propyl]-amide; 2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid-[1-benzyl-3-(1,1-dioxo-tetrahydro-1-thiophen-2-yl)-2-methoxy-3-oxo-propyl]-amide; and 2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid-[1-benzyl-3-(1,1-dioxo-hexahydro-1-thiopyran-2-yl)-2-methoxy-3-oxo-propyl]-amide; the prodrugs thereof, and the pharmaceutically acceptable salts of said compounds and prodrugs.
- 9. A pharmaceutical composition comprising a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or said prodrug; and a pharmaceutically acceptable carrier, vehicle, or diluent.
- 10. A method of treating a condition selected from the group consisting of atherosclerosis, diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, hyperglycemia, hypertension, tissue ischemia, and mycardial ischemia, which comprises administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or said prodrug; or a pharmaceutical composition comprising said compound of claim 1, or said prodrug thereof, or said pharmaceutically acceptable salt of said compound or said prodrug, and a pharmaceutically acceptable carrier, vehicle, or diluent.
- 11. A method of claim 10 wherein said condition is diabetes.
- 12. A method of inhibiting glycogen phosphorylase which comprises administering to a mammal in need of such inhibition, a glycogen phosphorylase inhibiting amount of a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or said prodrug; or a pharmaceutical composition comprising said compound of claim 1, or said prodrug thereof, or said pharmaceutically acceptable salt of said compound or said prodrug, and a pharmaceutically acceptable carrier, vehicle, or diluent.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application No. 60/424,627 filed Nov. 7, 2003.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60424627 |
Nov 2002 |
US |